Women’s cancers remain among the most challenging areas in oncology, marked by complex biology, limited early detection methods, and significant treatment gaps. This MVA Oncology Network meeting brings together experts from industry, academia, and clinical practice to explore how we can accelerate innovation and improve outcomes in these critical disease areas.
Through a series of presentations from both industry partners, clinicians and academia, we will examine:
- The latest therapeutic developments in gynecological and breast cancers
- Collaborative models that connect researchers, clinicians, and patients
- Strategic and clinical challenges in oncology drug development
The event will round off with a panel discussion focusing on shared obstacles and actionable solutions aimed at advancing cross-sector collaboration in women’s cancer research and care.
Participants will have ample opportunities to network and exchange insights across the Medicon Valley ecosystem.
Date: Tuesday, 23rd September 2025
Time: 14:00-18:30
Venue: Genmab, Carl Jacobsens Vej 30, 2500 Valby, Copenhagen – Auditorium
Program:
| 14.00 | Registration and Networking |
| 14:30 | Welcome Katrine Brems Olsen, Head of Networks, Medicon Valley Alliance Ulf Forssmann, Vice President, Medical Head of Early Development, Genmab |
| 14:35 | The Changing Treatment Landscape in Endometrial Cancer Mansoor Raza Mirza, Chief Oncologist, Rigshospitalet and CMO, Acrivon |
| 15:00 | Unlocking ADC Potential in Gynecologic Cancers Kathy Amiri, Vice President, Head of Global Medical Affairs Strategy, Solid Tumors, Genmab |
| 15:30 | The power of partnerships to drive progress in women’s health Caroline Ford, Professor & Group Leader – Gynaecological Cancer Research Group, University of New South Wales, Australia |
| 16:00 | Coffee Break |
| 16:30 | Driven by Compassion, Powered by Innovation: A Pharma Perspective on the Evolution of Breast Cancer Nicholas Sroczynski, Nordic Medical Manager, Oncology (Breast), Daiichi Sankyo Nordics |
| 16:50 | The Lifecourse View: Rethinking When Breast Cancer Risk Factors Emerge Jennifer Lyn Baker, Research Group Leader, Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital |
| 17:15 | Panel Discussion: Obstacles and Possibilities in Women’s Cancer Moderated by Ulf Forssmann, Vice President, Medical Head of Early Development, and Jesper Kofoed Damm, Medical Advisor, EU Medical Affairs, Genmab |
| 18:00 | Networking, Drinks and Light Catering |
| 18:30 | End of meeting |
Speakers
 |
Dr. Mansoor Mirza is a distinguished, highly accomplished clinician with a stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades. He most recently joined Acrivon Therapeutics Inc. as Chief Medical Officer, while he is serving as Chief Oncologist at Copenhagen University Hospital and as the Medical Director of the Nordic Society of Gynaecological Oncology. He has broad experience in clinical protocol development, trial conduct and clinical trial regulations, and is a globally recognized key opinion leader in gynaecological cancers. |
 |
Kathy Amiri, PhD is a biopharmaceutical executive with over 20 years of oncology experience, currently heading Global Medical Affairs Strategy for the oncology portfolio at Genmab. Previously, she held leadership roles at Roche and Celgene, where she directed Medical Affairs strategy, led global trial programs, and supported product launches across solid tumors. She is respected for her ability to bridge science and strategy, guiding teams and organizations toward impactful, patient-focused innovation in oncology. |
 |
Professor Caroline Ford is an Australian scientist and women’s health advocate with dual appointments in Sydney and Copenhagen. She leads major translational research projects in ovarian cancer, endometrial cancer and endometriosis. Her team collaborates closely with clinicians, industry and people with gynaecological diseases and cancers to improve detection, treatment and outcomes for these overlooked conditions. In addition to her research program, Prof Ford is a vocal and engaged advocate for women’s health, science communication and gender equity in STEMM using social and mainstream media, educational platforms, and community engagement to increase awareness and develop practical strategies to address these issues. |
 |
Nicholas Z. Sroczynski holds a Ph.D. in Molecular Biology, with a strong background in life sciences and a strategic role at Daiichi Sankyo Nordic. Based in Denmark, he offers deep insights into how a pharmaceutical company like Daiichi Sankyo drives innovation and collaboration in breast cancer research and treatment. |
 |
Jennifer L. Baker, Ph.D. is Head of Research in Lifecourse Epidemiology at the Center for Clinical Research and Prevention, Copenhagen University Hospital–Bispebjerg and Frederiksberg. For over 20 years, she has led major government- and foundation-funded projects using big data to study the causes and consequences of obesity across the lifecourse. She serves on international expert committees in obesity and cancer that shape research and policy worldwide, advancing both public health and scientific knowledge. |
Deadline for registration is Friday 19th September 2025.
The MVA Oncology network
Joining the MVA Oncology Network is free of charge but is limited to Medicon Valley Alliance members. Non-member organizations and companies are welcome to attend one network event to evaluate the relevance in joining the network. For more information, please contact Katrine Brems Olsen at kbo@mva.org
| Organized by | Hosted by |
 |
 |